Merck has acquired Massachusetts-based Erbi Biosystems, a developer of the 2 ml micro-bioreactor platform technology, known as the “Breez™”.
Erbi’s differentiated 2 ml micro-bioreactor platform technology, Breez™, enables rapid lab testing for bioprocessing scale up
Allows Merck to offer full range of bioreactors, from 2ml to 2000L
Adds to company’s expertise in monoclonal antibody (mAb) process development